Hyperfine Inc (HYPR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.81-2.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · HYPR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -10.3% |
| Our one-year growth estimate | diamond | 41.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 52.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
HYPR — earnings in line
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Hyperfine, Inc. issued a press release announcing its results for the second quarter ended June 30, 2026 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subje…
Why it matters: Better margins show improved cost management. This means more profit potential.
Supportive ifGross profit margins reported above 10% for Q2.
Worry ifGross profit margins were under 10% for Q2. This shows ongoing problems.
Why it matters: A return to faster revenue growth could signal a positive shift in the company's performance.
Supportive ifRevenue growth re-accelerates back toward its previous highs of near 10%.
Worry ifRevenue growth is slowing down or staying the same.
Why it matters: The earnings report will provide key insights into revenue and cash burn progress.
Watch forEarnings report shows positive revenue and cash burn results.
Also watch forEarnings report shows negative results for revenue and cash burn.
Why it matters: Better margins show that costs are managed well. This means products are making more money.
Supportive ifGross profit margin is over 51% in Q2. This shows good cost control.
Worry ifGross profit margin is below 40%. This raises worries about making money.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$215 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $738 loss on $10,000 · 7.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,336 loss on $10,000 · 63.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Meeting this growth target would confirm that Hyperfine is on track to achieve its 2026 revenue goal.
Supportive ifQ3 revenue growth is at least 55% year-over-year compared to Q3 2025.
Worry ifQ3 revenue growth is below 55% year-over-year compared to Q3 2025.
Why it matters: Staying within this range shows Hyperfine is keeping costs down while growing.
Supportive ifFull year cash burn is reported between $26 million and $28 million.
Worry ifFull year cash burn exceeds $28 million.
Why it matters: New clinical evidence can help more people use the Swoop system in hospitals.
Watch forAt least two new peer-reviewed publications on the Swoop system are released.
Also watch forNo new peer-reviewed articles on the Swoop system are published.